Brigatinib for -positive metastatic non-small-cell lung cancer: design, development and place in therapy.

Despite the benefits of first and second generation anaplastic lymphoma kinase () inhibitors in the management of -rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in -positive NSCLC.